CDH17 and familial pancreatic carcinoma: Compound 51 also inhibited DDR1-mediated cadherin switching, suppressed colony development of pancreatic cancer cells, exhibited good PK properties, and displayed a promising therapeutic activity through oral administration in orthotropic syngeneic pancreatic cancer models.